Biotheus Inc.

18 clinical trials · Sponsor

Record	Firm	Date
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer (NCT07133750)	Biotheus Inc.	2025-08-19
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC (NCT06584071)	Biotheus Inc.	2024-12-01
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer (NCT06616532)	Biotheus Inc.	2024-11-13
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC (NCT06419621)	Biotheus Inc.	2024-06-11
A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours (NCT05537051)	Biotheus Inc.	2023-10-30
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC (NCT05756972)	Biotheus Inc.	2023-06-26
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC (NCT05844150)	Biotheus Inc.	2023-06-01
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN (NCT05879055)	Biotheus Inc.	2023-05-17
A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours (NCT05607563)	Biotheus Inc.	2022-11-21
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC (NCT05918133)	Biotheus Inc.	2022-07-01
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC (NCT05879068)	Biotheus Inc.	2022-05-27
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma (NCT05864105)	Biotheus Inc.	2022-04-22
A Study of PM1022 in Patients With Advanced Tumors (NCT05867771)	Biotheus Inc.	2022-04-11
Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors (NCT05862831)	Biotheus Inc.	2021-09-07
PM8002 in the Treatment of Patients With Advanced Solid Tumors (NCT05918445)	Biotheus Inc.	2021-03-09

Track Biotheus Inc. automatically

Every clearance here is in the API, with alerts when new ones post.